Windtree Therapeutics is set to be removed from the Nasdaq Capital Market because it didn’t meet the exchange’s listing criteria, a development that caused a significant drop in the company’s stock value.
Windtree’s Stock Price Leads to Nasdaq Exit; OTC Markets Next
According to a filing with the Securities and Exchange Commission (SEC), Nasdaq formally notified Windtree of the delisting on August 19, 2025. The suspension of trading on Nasdaq is scheduled to begin on August 21 when the market opens.
Windtree anticipates that its shares will continue to be available for public trading under the symbol WINT, but on the Over-the-Counter (OTC) markets. The firm has submitted a request to be listed on the OTCID tier, although approval is not assured.
If the application is approved, trading on the OTC market typically involves reduced trading activity, less visibility, and limited access for investors compared to the Nasdaq. This raises concerns about the company’s capacity to secure additional funds in the future.
The primary reason for the delisting is Windtree’s failure to adhere to Nasdaq Listing Rule 5550(a)(2), which requires a minimum share price of $1. While Windtree previously acknowledged being out of compliance, it couldn’t elevate its stock price above the required level within the given timeframe. Thus, Nasdaq’s decision is a reflection of both regulatory requirements and the stock’s performance.
Jed Latkin, Windtree’s Chief Executive Officer, signed the SEC filing affirming the company’s position. He reassured stakeholders that Windtree’s operations will continue without interruption and that the company will fulfill all necessary reporting obligations to the SEC.
Last month, Windtree garnered attention outside of the biotechnology sector by creating a corporate treasury using Binance Coin (BNB). This unconventional approach mirrors strategies employed by companies holding Bitcoin as part of their financial assets. It also established Windtree as one of the few publicly listed healthcare firms connecting biotech funding with investments in cryptocurrency.
Windtree Stock Plummets as BNB Shows Strength
The delisting announcement immediately affected investor sentiment. Windtree’s stock price plummeted by over 76% in a single trading day, dropping from a closing price of $0.48 to just $0.11. Data from TradingView indicates that the stock has lost over 90% of its value in the past month and more than 99% since the start of the year. This steep decline underscores significant investor apprehension as the business transitions away from a major stock exchange to the OTC market.
Conversely, the news had no adverse effects on the price of BNB. The cryptocurrency rose above $850, increasing by over 3% in a 24-hour period. TradingView data reported BNB closing at $852.14, adding to its impressive performance in 2025. The digital token is up over 12% for the month, 30% over the last six months, and more than 52% over the past year.
Paul
Paul Adedoyin is a crypto journalist with 4+ years experience who provides timely news, in-depth research, and insightful content to inform and empower his audience. His works have been featured on sites such as CryptoMode, CryptoNewsFlash among others.
He holds a degree in Geophysics from OAU, Nigeria. When he’s not writing, he loves watching soccer and reading educative journals.
He can be reached via [email protected]
Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.
Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.
✓ Share: